Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from NICE

‘Next generation’ treatment to cure leukaemia given NHS approval

‘The biggest thing it offers is hope,’ says patient involved in clinical trial which cured cancer in significant portion of leukaemia sufferers

The Independent UK

Health benefits of Mounjaro reverse when jabs halted, study says

Researchers found benefits including reduced blood pressure were reversed after patients ceased taking the jab

The Independent UK

‘Important moment’ as at-home heart treatment approved for NHS use

About 1,500 patients in England and Wales live with the rare heart condition

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Prozac ‘no better than placebo’ for treating children with depression, experts say

Exclusive: Clinical guidelines should change to avoid exposing young people to potentially harmful side-effects, researchers say

The Guardian - UK

Now AI will be used to help NHS doctors spot pre-cancerous growths

The technology will be used to spot early signs of bowel cancer

The Independent UK

Congressman Buys Shares Of Small AI Company You've Probably Never Heard Of

Many people around the world have made investments in artificial intelligence stocks over the last year. When a member of Congress buys shares of a $7 billion AI-related company, investors likely take notice.

Benzinga

NICE Just Showed Why Its AI-First Strategy Is Winning

NICE Ltd (NASDAQ:NICE) shares rose Thursday after the company reported its third-quarter results, beating street estimates.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

3 Beaten-Down Stocks With Rebound Potential This Earnings Season

These firms present at least a modest risk/reward profile, but could be preparing for a share price turnaround depending upon how earnings season plays out.

MarketBeat

NHS won’t get cutting-edge drugs unless it pays more, says AstraZeneca boss

Pascal Soriot calls for cost-effectiveness thresholds to undergo ‘substantial adjustment based on inflation’

The Guardian - UK

NHS rollout of new eczema cream could benefit more than 62,000 people in England

Chronic hand eczema causes the hands to become dry, sore, cracked and itchy, making tasks difficult.

Evening Standard

Moukoko’s arrival at FC Copenhagen offers a cautionary tale for any wonderkid

Once labelled ‘the biggest talent in the world’, the former Borussia Dortmund forward has endured form fluctuations, controversy and criticism

The Guardian - UK

"We'd been going down well until that happened": How The Nice offended Leonard Bernstein and the US Embassy

The story of the song that crystallised the burgeoning prog-rock movement and turned The Nice into one of the most controversial bands of the day

Louder

Study shows prostate cancer screening can ‘reduce deaths’ as UK scheme assessed

Experts called for a ‘targeted’ screening approach to prevent overdiagnosis.

Evening Standard

Prostate cancer screenings could save lives but experts warn of major risks

Prostate cancer is the most common cancer among men in the UK, with more than 64,000 diagnoses anually

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Prostate cancer drug that can halve death risk to be offered to thousands in England

At least 6,000 men a year with hormone-sensitive cancer to get access to darolutamide, which blocks growth with fewer side-effects

Evening Standard

Prostate cancer sufferers in ‘postcode lottery’ to get new drug, says charity

It comes as concerns were raised that a new drug approved for NHS use will not be given to eligible patients.

The Independent UK

New ‘gentler’ treatment for prostate cancer gets green light but not all men will have access to it

It comes as concerns were raised that a new drug approved for NHS use will not be given to eligible patients

Benzinga

UK Health Agency Recommends GSK-Backed ViiV Healthcare's Apretude As Injectable HIV Treatment

The U.K.’s National Institute for Health and Care Excellence (NICE) is recommending a treatment from a firm jointly owned by GSK Plc (NYSE:GSK), Pfizer Inc (NYSE:PFE) and Shionogi Inc.

Get all your
news in one place.

100's of premium titles.
One news app.

Euronews

England and Wales to get long-lasting HIV prevention jab for first time

The drug, known as cabotegravir, must be administered every two months.

The Guardian - UK

‘Gamechanging’ HIV prevention jab to be approved for England and Wales

Long-acting injection offers alternative to daily pills taken to protect against the virus

The Independent UK

‘Game-changing’ HIV jab to be offered in England and Wales

The rollout is expected to begin around three months after Nice publishes its final guidance later this year

Evening Standard

‘Game-changing’ HIV prevention jab to be offered in England and Wales

The National Institute for Health and Care Excellence recommended the injection for people at risk of HIV who are unable to take oral PrEP.

Evening Standard

Patients with brain cancer express disappointment after drug rejected for NHS

Patients who have taken the drug in clinical trials report remarkable results, including their tumours shrinking.

The Independent UK

Brain cancer patients left ‘devastated’ as new drug is rejected for NHS use

Patients who have taken the drug in clinical trials report remarkable results, including their tumours shrinking

The Independent UK

Almost 300,000 protest against pushing up NHS drug prices

Campaign group 38 Degrees said the Government ‘must reject demands for higher prices for vital NHS medicine’.

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

UEFA Champions League

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.